Specifically, we revealed that the inhibition of NEK6 by genetic modification or ZINC05007751, a NEK6 selective inhibitor, could enhance the anti-tumor effects of palbociclib (a CDK4/6 inhibitor) in cell lines, patient-derived organoids and mouse models of EC. Here, NEK6 is linked to neoplasm.